JPM26: Ypsomed commits to self-care delivery devices in new strategic plan
Between 2020 and 2025, Ypsomed's delivery device business grew at a CAGR of 24% to achieve a value of CHF 501 million in 2025.
Comment & Opinion
JPM26: Opus Genetics builds momentum in rare retinal gene therapy
JPM26: Butterfly Network aims to close the global medical imaging gap
JPM26: Rakuten Medical unveils transformative photoimmunotherapy platform
JPM26: ICU Medical hopeful to ‘get out of the woods’ soon
JPM26: Integra resets by fixing supply and riding reimbursement tailwinds
JPM26: Ambu strengthens growth outlook as single-use endoscopy adoption grows
Intuitive Surgical expands platforms despite market headwind
